why choose us

First received: February 24, 2023

Clinical Trial: A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

Study Status: Completed

Recruit Status: RECRUITING

Condition: Atrial Fibrillation

Study Type: INTERVENTIONAL


Official Title: A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participan

Brief Summary: The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non- central nervous system (CNS) systemic embolism.

Read more